Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
By Alan Harrison The USPTO issued a Guidance Update, effective July 17, 2024, to address the evolving landscape of patent eligibility, particularly in relation to artificial intelligence (AI). It seeks to clarify and update the [Read More…]
By Meghan E. McDermott Today, branding is everything – it is arguably one of the most important assets a company can have. So, whether you are starting a new brand or re-branding, any type of [Read More…]
Copyright law includes an interesting clause at 17 U.S.C. § 203: (3) Termination of the grant may be effected at any time during a period of five years beginning at the end of thirty-five years [Read More…]